Advertisement

Topics

Latest "CAFC Affirms Apotex Biosimilars Infringe Amgen Patent" News Stories

07:54 EST 13th December 2018 | BioPortfolio

Here are the most relevant search results for "CAFC Affirms Apotex Biosimilars Infringe Amgen Patent" found in our extensive news archives from over 250 global news sources.

More Information about CAFC Affirms Apotex Biosimilars Infringe Amgen Patent on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about CAFC Affirms Apotex Biosimilars Infringe Amgen Patent for you to read. Along with our medical data and news we also list CAFC Affirms Apotex Biosimilars Infringe Amgen Patent Clinical Trials, which are updated daily. BioPortfolio also has a large database of CAFC Affirms Apotex Biosimilars Infringe Amgen Patent Companies for you to search.

Showing "CAFC Affirms Apotex Biosimilars Infringe Amgen Patent" News Articles 1–25 of 3,100+

Thursday 13th December 2018

PredictImmune Awarded Innovate UK Grant to Apply its Biomarker-Based Technology towards the Prediction of Drug Response in IBD.

Developer of the PredictSURE IBD™ prognostic test awarded £100K from Innovate UK’s ‘Precision medicine technologies: shaping the future’ fund to support feasibility study. PredictImmune, developer of prognostic tools to guide treatment of patients with immune-mediated diseases, announced today that it has been awarded a grant of £100,000 by I...


Innovent Announces Two Clinical Studies with the Anti-VEGF Monoclonal Antibody IBI305, a Biosimilar Candidate to Avastin (Bevacizumab), Met Primary Endpoints

SUZHOU, China, Dec. 13, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class China-based biopharmaceutical company that develops and commercializes high quality drugs, announced today that IBI305, a recombinant humanized anti-VEGF monoclonal antibody being developed as a potential biosimilar to Avastin (Bevacizumab), has met pre-defined primary endpoints in two r...

Wednesday 12th December 2018

Masimo Founder and CEO Joe Kiani Honored with First IP Champion Award

The Intellectual Property Owners Education Foundation Promotes the Understanding of Intellectual Property Laws and Their Value to Society Masimo (NASDAQ: MASI) Founder and CEO Joe Kiani was honored last night at the 2018 IPO Education Foundation Awards Dinner with the first ever IP Champion Award. The


#news #biotech Cancer-killing virus plus PD-1 and MEK inhibitors make for a 3-pronged attack on melanoma

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Cancer-killing virus plus PD-1 and MEK inhibitors make for a 3-pronged attack on melanoma .When Amgen’s cancer-killing virus Imlygic was approved in late 2015, experts expected it would … Continue reading →

FDA issues new guidances to advance biosimilars

Amgen donate $2m towards increasing #diversity in clinical trials http://bit.ly/2QQBQu8  @Amgen #clinicaltrials #pharma #equality

Amgen donate $2m towards increasing #diversity in clinical trials http://bit.ly/2QQBQu8  @Amgen #clinicaltrials #pharma #

Geneva Health Solutions Hits Critical Milestones Driving Growth; Predicts Cardiac Data Explosion in 2019

Geneva Health Solutions (GHS), the leading cloud-based technology platform and service for managing data from implantable cardiac devices, announces triple-digit revenue growth in 2018, an indicator of the explosive growth of implantable cardiac device data expected in 2019. This year, GHS has also tripled its client base and workforce, quadrupled t...

Report Highlights USDA Technology Innovations

The U.S. Department of Agriculture (USDA) developed 166 new inventions and 66 patent applications in the 2017 fiscal year, according to their Annual Report on Technology Transfer released this month."USDA research not only improves agriculture, but it also creates business opportunities and jobs through innovations affecting all areas of daily life...

Caribou Biosciences Appoints Dr. Natalie Sacks to Board of Directors

Caribou Biosciences, Inc., a leading genome editing company, announced today that it has appointed Natalie Sacks, MD to its Board of Directors. Dr. Sacks is an accomplished industry leader and oncology expert who has played a key role in the development and approval of several oncology therapeutics. “We are excited to welcome Dr. Sacks to our Bo...

Singulex Receives New, Broad Patent for Highly Sensitive Methods for Analysis of Troponin

Singulex announced today the granting of a significant European patent (EP 3168618) covering methods for determining myocardial infarction using any high sensitivity cardiac troponin assay with a sensitivity < 5 pg/mL. “The global clinical market is rapidly adopting high sensitivity cardiac troponin assays to better manage patients suspected ...

Transplant Complications Drug Development Pipeline Review, 2018 [Report Updated: 30112018] Prices from USD $3396

Transplant Complications Drug Development Pipeline Review, 2018SummaryThis report provides an overview of the pipeline landscape for transplant complications. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for graftversushost disease GVHD, liver transplant rejection, kidney transplant rejection and lung transplant rej...

Amgen donate $2m towards increasing #diversity in clinical trials http://bit.ly/2QQBQu8  @Amgen #clinicaltrials #pharmapic.twitter.com/Pcw4byntag

Amgen donate $2m towards increasing #diversity in clinical trials http://bit.ly/2QQBQu8  @Amgen #clinicaltrials #pharma pic.twitter.com/Pc

Amgen donate $2m towards increasing diversity in clinical trials

American multinational Amgen has teamed up with the Lazarex Cancer Foundation in support of an initiative aimed at increasing access to clinical trials for those of all backgrounds, in the United States. The Thousand Oaks-based firm has contributed $2 million to Lazarex's IMPACT (IMproving Patient Access to Cancer Clinical Trials) programme, which is focused on improving patient enrolment retentio...

Amgen, Lazarex Cancer Foundation join hand to support more access to clinical trials for cancer patients in US

Amgen and the Lazarex Cancer Foundation, a non─profit organization focused on improving patient access to cancer clinical trials, have teamed up to support more equitable access to clinical trials for cancer patients in

Insulin biosimilars? US FDA readies market for entry

From March 2020, insulin medication will be regulated as a biologic drug, allowing biosimilar competition in a âwatershed moment for insulin productsâ.

Canadian Originators Hit A New Low On Research Spend

Canada’s brand industry has failed to meet its R&D spending commitment for the 15th consecutive year, according to local off-patent...   

US Appeals Court Upholds Livalo Patents Without Comment, Snubbing Amneal

Shot down at the district court level, Amneal was ploughing a lonely furrow in patent-litigation proceedings over Kowa Pharmaceuticals’ Livalo...   

Mayne Pharma receives FDA approval of Tolsura™ (SUBA®-itraconazole capsules) for the treatment of certain fungal infections

ADELAIDE, Australia, Dec. 12, 2018 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Tolsura™ (SUBA®-itraconazole) 65mg capsules. Tolsura is a new formulation of itraconazole indicated for the treatment of certain systemic fungal infections in adult patients. Tolsu...

Tuesday 11th December 2018

Amgen partners with Magellan on patient care for difficult-to-treat diseases

Amgen has entered into a partnership with Magellan Rx Management to improve care for patients suffering with chronic, difficult-to-treat diseases....Read More... The post Amgen partners with Magellan on patient care for difficult-to-treat diseases appeared first on Pharmaceutical Technology.

FDA Expands on Biologics and Biosimilars Action Plan, Especially for Diabetes Products

Yesterday, the agency and Gottlieb doubled-down on the Action Plan and added to it. The FDA released two new draft Q&A guidance documents on biosimilar development and two final guidance documents on the same topics, as well as a proposed amendment to the definition of a biological product.

Biotech updates 12/11: $CORT +32% patent news $TOCA $MRNS offerings $ACOR -15% GS downgrade $ITCI PDUFA Sep 27 $PTLA -7% CHMP delay Pipeline updates $AGLE $AQST $ARAV $ATNX $BLRX $EIGR $KNSA $SMMT $TRIL https://www.biopharmcatalyst.com/news/2018/corcept-

Biotech updates 12/11: $CORT +32% patent news $TOCA $MRNS offerings $ACOR -15% GS downgrade $ITCI PDUFA Sep 27

Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation

Delaware Court Rules Edwards Lifesciences Infringes Boston Scientific Patent MARLBOROUGH, Mass., Dec. 11, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that a jury in the United States (U.S.) District Court for the District of Delaware determined that the Boston Scientific U.S. patent 8,992,608 is valid and that Edwards Lifesciences' Sapien 3™ Aortic Valve infr...

Oral large-molecule drug collaboration launched by @Amgen and Entera Bio ($ENTX): http://ow.ly/opeW30mWGA7 

Oral large-molecule drug collaboration launched by @Amgen and Entera Bio ($ENTX): http://ow.ly/opeW30mWGA7 

Amgen And Magellan Rx Management Collaborate To Improve Patient Care For Chronic, Difficult-To-Treat Conditions

First Amgen-Pharmacy Benefit Manager Value-Based Agreement to Deliver Advanced Solutions for Osteoporosis and Migraine THOUSAND OAKS, Calif., Dec. 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a novel multi-year collaboration with Magellan Rx Management, the pharmacy benefit management division of Magellan Health, that will leverage each company's capabilities and resources to id...

Amgen to use Entera Bio's platform for oral delivery of large molecule drugs https://www.firstwordpharma.com/node/1610763  $AMGN

Amgen to use Entera Bio's platform for oral delivery of large molecule drugs https://www.firstwordpharma.com/node/1610763  $AMGN


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks